Survodutide Phase 3: what the SYNCHRONIZE-1 obesity trial found

What the source reports

A Phase 3 trial published in the New England Journal of Medicine tested survodutide in adults with obesity or overweight and at least one related complication, but without type 2 diabetes. Survodutide is an investigational once-weekly injection designed to activate both the GLP-1 and glucagon receptors.

At week 76, the trial's treatment-regimen analysis estimated average body-weight changes of −12.2% with survodutide 3.6 mg, −13.0% with 6.0 mg and −5.4% with placebo. This analysis incorporated early treatment discontinuation, use of prohibited weight-management medicines and prolonged dose escalation.

Both survodutide groups met the trial's two primary endpoints against placebo. The result is late-stage evidence that the medicine can reduce weight in the population studied; it is not an approval, a direct comparison with an existing medicine or proof of long-term health benefit.

How SYNCHRONIZE-1 worked

The randomised, double-blind trial enrolled 725 participants and assigned them in equal proportions to once-weekly survodutide adjusted up to 3.6 mg, survodutide adjusted up to 6.0 mg or placebo. All groups also received counselling on a reduced-calorie diet and increased physical activity.

Participants had a body-mass index of at least 30, or at least 27 with one or more obesity-related complications. People with type 2 diabetes were excluded. At baseline, average age was 47.1 years, average body weight was 108.8 kg and average BMI was 37.9; 40.6% of participants were men.

The two primary outcomes were percentage change in body weight and the proportion of participants losing at least 5% of their starting weight by week 76. The trial was conducted at multiple sites across 14 countries.

Why two weight-loss numbers appear in coverage

The paper's main treatment-regimen estimand asks what happened across the assigned treatment strategy, including the effects of stopping treatment and certain other events. On that basis, average weight reduction was 12.2% with 3.6 mg and 13.0% with 6.0 mg, compared with 5.4% for placebo.

A separate efficacy estimand modelled the effect if participants had remained on treatment for the full study. That analysis estimated reductions of 15.3% and 16.6% with the two survodutide doses, compared with 3.2% for placebo. The larger 16.6% figure is therefore not the result for everyone originally assigned to treatment regardless of discontinuation.

Both estimands answer legitimate but different questions. Reporting only the larger efficacy-estimand number can obscure the practical effect of tolerability and persistence, while reporting only the treatment-regimen result does not isolate the effect among people who remain on treatment.

How many participants lost at least 5%?

In the treatment-regimen analysis, 72.6% of participants assigned to survodutide 3.6 mg and 71.9% assigned to 6.0 mg lost at least 5% of their starting weight. The corresponding estimate in the placebo group was 46.3%.

The relatively large placebo-group change occurred in a trial where all participants received lifestyle counselling and the analysis incorporated events such as use of other prohibited obesity medicines. It does not make the randomised comparison invalid, but it is important context for the placebo-adjusted difference.

Threshold outcomes describe the proportion of a study group crossing a defined line. They do not show how an individual will respond, whether weight loss will be maintained after treatment stops or whether treatment will improve outcomes such as heart attacks, strokes or survival.

Gastrointestinal effects and discontinuation

Gastrointestinal adverse events were the most common side effects. They were reported in 80.9% of the 3.6 mg group, 89.7% of the 6.0 mg group and 47.9% of the placebo group, and were generally described as mild or moderate.

Adverse events led to permanent treatment discontinuation in 23.7% of participants assigned to 3.6 mg, 24.8% assigned to 6.0 mg and 5.4% assigned to placebo. Gastrointestinal events accounted for much of that difference and were more prominent during dose escalation.

No deaths were reported. A 725-person trial can characterise common events over 76 weeks, but it cannot reliably identify very rare harms or establish the safety profile that would emerge with much wider and longer use.

What the dual mechanism is intended to do

GLP-1 receptor activity is associated with reduced appetite and increased fullness. Survodutide also activates the glucagon receptor, a pathway involved in energy and liver metabolism. The research hypothesis is that combining those signals may influence body weight and metabolic health through complementary effects.

A mechanism is not the same as a clinical outcome. SYNCHRONIZE-1 established a weight difference against placebo in adults without diabetes; it was not designed to prove that glucagon-receptor activity prevents cardiovascular disease or provides a unique benefit over another obesity medicine.

Survodutide is also being studied in metabolic liver disease and in a separate cardiovascular-outcomes programme. Those trials address different populations and outcomes and should not be treated as though SYNCHRONIZE-1 has already answered their questions.

Why this is not a league table

SYNCHRONIZE-1 compared survodutide with placebo, not with semaglutide, tirzepatide, retatrutide or another active treatment. Percentages from separate trials cannot establish which medicine is more effective because trial populations, duration, dose flexibility, lifestyle support and methods for handling missing data differ.

The study excluded people with type 2 diabetes and tested two target doses under a defined escalation schedule. Its average result cannot be transferred directly to other populations or to unregulated products sold online under the survodutide name.

Survodutide remains investigational and is not approved for routine use. The trial product and monitoring used in a regulated study are not equivalent to a product marketed as a research peptide.

Funding and evidence still to come

Boehringer Ingelheim funded SYNCHRONIZE-1 and is responsible for survodutide's global development and commercialisation under a licence from Zealand Pharma. Several authors were employees of the sponsor, and other authors disclosed relationships with pharmaceutical companies.

Sponsor funding does not by itself determine whether a randomised result is reliable, but sponsor involvement, the prespecified analysis, complete adverse-event reporting, regulatory review and independent scrutiny all matter when interpreting a potential commercial medicine.

The wider Phase 3 programme includes participants with type 2 diabetes, metabolic liver disease and cardiovascular or kidney risk. Full results from those studies are needed to understand effectiveness and safety across different clinical groups.

What remains uncertain

It is not yet known whether survodutide will receive regulatory approval, what indication or dosing flexibility a regulator might accept, or how its benefit–risk balance would compare directly with approved treatments.

SYNCHRONIZE-1 does not establish long-term weight maintenance after discontinuation, cardiovascular protection, reduced mortality or routine-care persistence. The sizeable difference in adverse-event discontinuation makes longer and broader tolerability data especially relevant.

The trial also cannot determine whether the glucagon component produced a distinct clinical advantage. A direct active-comparator design or other carefully controlled evidence would be needed to answer that question.

Bottom line

In a 76-week Phase 3 trial involving 725 adults without type 2 diabetes, survodutide produced statistically greater average weight reduction than placebo. The main treatment-regimen analysis estimated reductions of 12.2% and 13.0% at the two doses, compared with 5.4% for placebo.

The same trial also showed why efficacy headlines need tolerability context: gastrointestinal effects were very common and about one quarter of participants assigned to survodutide permanently discontinued treatment because of adverse events. Survodutide remains an investigational medicine awaiting further evidence and regulatory assessment.